Adenosine signalling has long been a target for drug development, with adenosine itself or
its derivatives being used clinically since the 1940s. In addition, methylxanthines such as …

In the 10 years since our previous International Union of Basic and Clinical Pharmacology
report on the nomenclature and classification of adenosine receptors, no developments …

Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the
world. There is growing evidence that they could also be promising therapeutic targets in a …

Adenosine is formed inside cells or on their surface, mostly by breakdown of adenine
nucleotides. The formation of adenosine increases in different conditions of stress and …

Cardioprotective strategies aim to salvage myocardium from ischemia/reperfusion injury and
to reduce infarct size and its consequences. Different stimuli, acting at sites remote from the …

Intra-and extracellular adenosine levels rise in response to physiological stimuli and with
metabolic/energetic perturbations, inflammatory challenge and tissue injury. Extracellular …

Remote ischemic conditioning (RIC) is a therapeutic strategy for protecting organs or tissue
against the detrimental effects of acute ischemia-reperfusion injury (IRI). It describes an …

The purine nucleoside adenosine is an important regulator within the cardiovascular system,
and throughout the body. Released in response to perturbations in energy state, among …

Adenosine, formed primarily via hydrolysis of 5′-AMP, has been historically dubbed a
“retaliatory” metabolite due to enhanced local release and beneficial actions during …

Cisplatin is a commonly used antineoplastic agent that produces ototoxicity that is mediated
in part by increasing levels of reactive oxygen species (ROS) via the NOX3 NADPH oxidase …